Sartorius Stedim Biotech (DIM) Q2 2025 earnings summary

Executive summary

• Group sales revenue grew 6% in constant currencies in H1 2025, with strong recurring consumables demand driving margin expansion to nearly 30%; all regions contributed to growth.

• Bioprocess Solutions (BPS) saw sales rise nearly 9% in constant currencies, led by consumables, while equipment sales remained soft; Lab Products & Services (LPS) sales declined by 4–4.8% due to weak end markets, though recurring business improved.

• Underlying EBITDA increased by 12–19.3% year-over-year, with the margin approaching or reaching 31%.

• Several new products were launched to enhance customer efficiency and productivity in molecule development and drug manufacturing.

• The Matec/MatTek acquisition closed July 1, expanding the LPS portfolio and expected to contribute positively to H2 results.

Financial highlights

• Group sales revenue reached €1,767 million (+6.1% constant currency), with underlying EBITDA up 11.9% to €527 million and margin up to 29.8%.

• Underlying EPS increased by 13.5–36.8% to €2.34–2.44; reported net profit up 33–48.2% to €81–154 million.

• Operating cash flow was €244.7–289 million, down year-over-year due to higher working capital; free cash flow rose to €122 million.

• CapEx ratio dropped to 9.1–9.5% in H1 2025.

Outlook and guidance

• Full-year 2025 guidance confirmed: group revenue up 6–7% in constant currencies (±2pp), BPS up 7%, LPS up 1%; EBITDA margin 29–31% for group, 31–32% for BPS, 22–23% for LPS.

• CapEx-to-sales ratio forecast at ~12.5–13%; net debt to underlying EBITDA targeted to improve to 2.5–3.5 by year-end.

• Matec/MatTek acquisition expected to add ~1pp to LPS full-year revenue.

• Guidance excludes potential tariff impacts; management expects limited effect from new US/EU tariffs.